Use of multiparametric magnetic resonance in the active surveillance of prostate cancer: An integrative review




Cancer of Prostate; Multiparametric Magnetic Resonance Imaging; Watchful Waiting


Introduction: Prostate cancer is the second most common malignancy in males, with an increasing incidence due to improvements in diagnostic methods, such as multiparametric magnetic resonance imaging (MRI). Given this, new therapeutic modalities, such as active surveillance (AV), which is indicated for low-risk prostate cancer, are gaining ground. Objective: To investigate the use of mpMRI for monitoring patients undergoing active surveillance as a treatment for prostate cancer. Methods: This is an integrative review carried out using the SciELO, PubMed ®, VHL and LILACS databases. In total, 389 studies were found, after applying the inclusion and exclusion criteria, 17 articles remained chosen. Results: 5,206 patients with prostate cancer were analyzed in 15 studies, as there was no sample in 2 selected articles. Some studies assessed that mpMRI was not sufficient for monitoring VA patients with prostate cancer, with an indication for supplementation with biopsy even when there was no indication of disease progression on mpMRI. Despite this, most of the selected studies concluded that mpMRI had a negative predictive value for prostate cancer progression and could be used for follow-up in VA patients, with improvement if related to other variables such as prostate-specific antigen levels. Conclusion: mpMRI is gaining importance in the evaluation of patients with prostate cancer, including the indication and follow-up of patients in VA. Despite some limitations, it can be used in conjunction with other components to assess disease progression.


Ânima Educação. (2014). Manual revisão bibliográfica sistemática integrativa: a pesquisa baseada em evidências. Equipe EaD.

Brasil. (2022). Instituto Nacional de Câncer. Estimativa 2023: incidência de câncer no Brasil / Instituto Nacional de Câncer. INCA.

Cantiello, F., Russo, G. I., Kaufmann, S., Cacciamani, G., Crocerossa, F., Ferro, M., De Cobelli, O., Artibani, W., Cimino, S., Morgia, G., Damiano, R., Nikolaou, K., Kröger, N., Stenzl, A., Bedke, J., & Kruck, S. (2019). Role of multiparametric magnetic resonance imaging for patients under active surveillance for prostate cancer: a systematic review with diagnostic meta-analysis. Prostate Cancer Prostatic Dis 22, 206–220.

Castillo, L. C., Morales, L. G., López, D. L., Segura, J. S., Rosa, J. V., Curado, F. J. A., Quesada, J. M., Pedregosa, A. B., Valiente, J. C., & Gómez, E. G. (2023). The role of multiparametric magnetic resonance in active surveillance of a low-risk prostate cancer cohort from clinical practice. Prostate.;83(8):765-772.

Chu, C. E., Cowan, J. E., Lonergan, P. E., Washington, S. L., Fasulo, V., de la Calle, C. M., Shinohara, K., Westphalen, A. C., & Carroll, P. R. (2022). Diagnostic Accuracy and Prognostic Value of Serial Prostate Multiparametric Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer. Eur Urol Oncol.;5(5):537-543.

Dall'Era, M. A., Albertsen, P. C., Bangma, C., Carroll, P. R., Carter, H. B., Cooperberg, M. R., Freedland, S. J., Klotz, L. H., Parker, C., & Soloway, M. S. (2012). Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol.;62(6):976-83.

Fujihara, A., Iwata, T., Shakir, A., Tafuri, A., Cacciamani, G. E., Gill, K., Ashrafi, A., Ukimura, O., Desai, M., Duddalwar, V., Stern, M. S., Aron, M., Palmer, S. L., Gill, I. S., & Abreu, A. L. (2021). Multiparametric magnetic resonance imaging facilitates reclassification during active surveillance for prostate cancer. BJU Int.;127(6):712-721.

Gallagher, K. M., Christopher, E., Cameron, A. J., Little, S., Innes, A., Davis, G., Keanie, J., Bollina, P., & McNeill, A. (2019). Four-year outcomes from a multiparametric magnetic resonance imaging (MRI)-based active surveillance programme: PSA dynamics and serial MRI scans allow omission of protocol biopsies. BJU Int.;123(3):429-438.

Hegde, J. V., Mulkern, R. V., Panych, L. P., Fennessy, F. M., Fedorov, A., Maier, S. E., & Tempany, C. M. (2013). Ressonância magnética multiparamétrica do câncer de próstata: uma atualização sobre técnicas de ponta e seu desempenho na detecção e localização do câncer de próstata. Imagem de ressonância J Magn; 37:1035.

Hettiarachchi, D., Geraghty, R., Rice, P., Sachdeva, A., Nambiar, A., Johnson, M., Gujadhur, R., Mcneill, M., Haslam, P., Soomro, N., Hameed, B. M. Z., Somani, B., Veeratterapillay, R., & Rai, B. P. (2021). Can the Use of Serial Multiparametric Magnetic Resonance Imaging During Active Surveillance of Prostate Cancer Avoid the Need for Prostate Biopsies? A Systematic Diagnostic Test Accuracy Review. Eur Urol Oncol.;4(3):426-436.

Hsiang, W., Ghabili, K., Syed, J. S., Holder, J., Nguyen, K. A., Suarez-Sarmiento, A., Huber, S., Leapman, M. S., & Sprenkle, P. C. (2021). Outcomes of Serial Multiparametric Magnetic Resonance Imaging and Subsequent Biopsy in Men with Low-risk Prostate Cancer Managed with Active Surveillance. Eur Urol Focus.;7(1):47-54.

Komisarenko, M., Martin, L. J., & Finelli, A. (2018). Revisão de vigilância ativa: critérios de seleção contemporâneos, acompanhamento, conformidade e resultados. Androl Urol.; 7 :243–255

Kumar, V., Aster, J. C., & Abbas, A. K. (2021). Robbins & Cotran Patologia: bases patológicas das doenças. 9ªed. Rio de Janeiro: Guanabara Koogan, 1421p.

Lee, C. H., Tan, T. W., & Tan, C. H. (2021). Multiparametric MRI in Active Surveillance of Prostate Cancer: An Overview and a Practical Approach. Korean J Radiol.;22(7):1087-1099.

Liss, M. A., Newcomb, L. F., Zheng, Y., Garcia, M. P., Filson, C. P., Boyer, H., Brooks, J. D., Carroll, P. R., Cooperberg, M. R., Ellis, W. J., Gleave, M. E., Martin, F. M., Morgan, T., Nelson, P. S., Wagner, A. A., Thompson, I. M. Jr., & Lin, D. W. (2020). Magnetic Resonance Imaging for the Detection of High Grade Cancer in the Canary Prostate Active Surveillance Study. J Urol.;204(4):701-706.

Luzzago, S., Piccinelli, M. L., Mistretta, F. A., Bianchi, R., Cozzi, G., Di Trapani, E., Cioffi, A., Catellani, M., Fontana, M., Jannello, L. M. I., Botticelli, F. M. G., Marvaso, G., Alessi, S., Pricolo, P., Ferro, M., Matei, D. V., Jereczek-Fossa, B. A., Fusco, N., Petralia, G., de Cobelli, O., & Musi, G. (2022). Repeat MRI during active surveillance: natural history of prostatic lesions and upgrading rates. BJU Int.;129(4):524-533.

Macleod, L. C., Yabes, J. G., Fam, M. M., Bandari, J., Yu, M., Maganty, A., Furlan, A., Filson, C. P., Davies, B. J., & Jacobs, B. L. (2020). Multiparametric Magnetic Resonance Imaging Is Associated with Increased Medicare Spending in Prostate Cancer Active Surveillance. Eur Urol Focus.;6(2):242-248.

Mamawala, M. K., Meyer, A. R., Landis, P. K., Macura, K. J., Epstein, J. I., Partin, A. W., Carter, B. H., & Gorin, M. A. (2020). Utility of multiparametric magnetic resonance imaging in the risk stratification of men with Grade Group 1 prostate cancer on active surveillance. BJU Int.;125(6):861-866.

Merriel, S. W. D., Pocock, L., Gilbert, E., Creavin, S., Walter, F. M., Spencer, A., & Hamilton, W. (2022). Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for detecting prostate cancer in symptomatic patients. BMC Med; 20:54.

Mussi, T. C. (2018). A ressonância magnética multiparamétrica de próstata nos dias atuais. Einstein (São Paulo);16(2):eMD4408.

O'Connor, L. P., Wang, A. Z., Yerram, N. K., Long, L., Ahdoot, M., Lebastchi, A. H., Gurram, S., Zeng, J., Harmon, S. A., Mehralivand, S., Merino, M. J., Parnes, H. L., Choyke, P. L., Shih, J. H., Wood, B. J., Turkbey, B., & Pinto, P. A. (2021). Changes in Magnetic Resonance Imaging Using the Prostate Cancer Radiologic Estimation of Change in Sequential Evaluation Criteria to Detect Prostate Cancer Progression for Men on Active Surveillance. Eur Urol Oncol.;4(2):227-234.

Raichi, A., Marcq, G., Fantoni, J.C., Puech, P., Villers, A., & Ouzzane, A. (2018). Surveillance active dans le cancer de prostate: évaluation de l’IRM dans la sélection et le suivi des patients. Progrès En Urologie; 28(8-9), 416–424.

Rosenzweig, B., Laitman, Y., Zilberman, D. E., Raz, O., Ramon, J., Dotan, Z. A., & Portnoy, O. (2020). Effects of "real life" prostate MRI inter-observer variability on total needle samples and indication for biopsy. Urol Oncol.;38(10):793.e13-793.e18.

Sartor, O. A. (2023). Risk factors for prostate câncer. UpToDate. Disponível em:

Sathianathen, N. J., Butaney, M., Bongiorno, C., Konety, B. R., Bolton, D. M., & Lawrentschuk, N. (2019). Accuracy of the magnetic resonance imaging pathway in the detection of prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis.;22(1):39-48.

Schiavina, R., Droghetti, M., Novara, G., Bianchi, L., Gaudiano, C., Panebianco, V., Borghesi, M., Piazza, P., Bianchi, F. M., Guerra, M., Corcioni, B., Fiorentino, M., Giunchi, F., Verze, P., Pultrone, C., Golfieri, R., Porreca, A., Mirone, V., & Brunocilla, E. (2021). The role of multiparametric MRI in active surveillance for low-risk prostate cancer: The ROMAS randomized controlled trial. Urol Oncol;39(7):433.e1-433.e7.

Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022). Estatísticas de câncer, 2022. CA Cancer J Clin; 72:7.

Stavrinides, V., Giganti, F., Trock, B., Punwani, S., Allen, C., Kirkham, A., Freeman, A., Haider, A., Ball, R., McCartan, N., Whitaker, H., Orczyk, C., Emberton, M., & Moore, C.M. (2020). Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. Eur Urol.;78(3):443-451.

Tempany, C. M. C., Carroll, P. R., & Leapman, M. S. (2023). The role of magnetic resonance imaging in prostate câncer. UpToDate. Disponível em:

Tempany, C. M. C., Carroll, P. R., Leapman, M. S. (2024). The role of magnetic resonance imaging in prostate câncer. UpToDate. Disponível em:

Thurtle, D., Barrett, T., Thankappan-Nair, V., Koo, B., Warren, A., Kastner, C., Saeb-Parsy, K., Kimberley-Duffell, J., & Gnanapragasam, V.J. (2018). Progression and treatment rates using an active surveillance protocol incorporating image-guided baseline biopsies and multiparametric magnetic resonance imaging monitoring for men with favourable-risk prostate câncer. BJUI; 122(1):59-65.

Turkbey, B., Rosenkrantz, A. B., Haider, M. A., Padhani, A. R., Villeirs, G., Macura, K. J., Tempany, C. M., Choyke, P. L., Cornud, F., Margolis, D. J., Thoeny, H. C., Verma, S., Barentsz, J., & Weinreb, J. C. (2019). Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. European urology, 76(3), 340–351.

Ullrich, T., Arsov, C., Quentin, M., Mones, F., Westphalen, A. C., Mally, D., Hiester, A., Albers, P., Antoch, G., & Schimmöller, L. (2020). Multiparametric magnetic resonance imaging can exclude prostate cancer progression in patients on active surveillance: a retrospective cohort study. Eur Radiol.;30(11):6042-6051.

US Preventive Services Task Force; Grossman, D. C., Curry, S. J., Owens, D. K., Bibbins-Domingo, K., Caughey, A. B., Davidson, K. W., Doubeni, C. A., Ebell, M., Epling, J. W. Jr., Kemper, A. R., Krist, A. H., Kubik, M., Landefeld, C. S., Mangione, C. M., Silverstein, M., Simon, M. A., Siu, A. L., & Tseng, C. W. (2018). Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. ;319(18):1901-1913.

Woo, S., Suh, C. H., Kim, S. Y., Cho, J. Y., & Kim, S. H. (2017). Diagnostic Performance of Prostate Imaging Reporting and Data System Version 2 for Detection of Prostate Cancer: A Systematic Review and Diagnostic Meta-analysis. Eur Urol.;72(2):177-188.



How to Cite

OLIVEIRA NETO, J. M. F. de .; FERREIRA FILHO, E. S.; MACHADO, M. H. de A. .; ABRITTA, R. T. R. . Use of multiparametric magnetic resonance in the active surveillance of prostate cancer: An integrative review. Research, Society and Development, [S. l.], v. 13, n. 3, p. e6113345286, 2024. DOI: 10.33448/rsd-v13i3.45286. Disponível em: Acesso em: 25 jun. 2024.



Review Article